EUVIMEDEUVIMED entdecken
Crossref

Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support

Ryan Brown, Katie E Smith, Mohamed M Shanshal, Anastasios Dimou, Konstantinos Leventakos, Kaushal Parikh, Aaron S Mansfield, Julian R Molina, Matthew P Goetz, Aminah Jatoi, Elizabeth Cathcart-Rake

Supportive Care in Cancer · 2025

DOI: 10.1007/s00520-025-10182-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Ryan Brown und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Social Support, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lactams, Macrocyclic. Die Arbeit nennt 26 Literaturangaben. Gefördert von: NIMHD NIH HHS, National Institute on Minority Health and Health Disparities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Social SupportLung NeoplasmsCarcinoma, Non-Small-Cell LungLactams, MacrocyclicLactamsAntineoplastic AgentsNeurocognitive DisordersHumansMaleFemaleAgedMiddle AgedAged, 80 and overRisk FactorsAdultRetrospective StudiesPyrazolesAminopyridines

Stichwörter der Autor:innen

AgeHospitalizationLorlatinibNeurocognitive adverse eventsSocial support

Substanzen

lorlatinibLactams, MacrocyclicLactamsAntineoplastic AgentsPyrazolesAminopyridines

Autor:innen und Institutionen

  • Department of Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
  • Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. jatoi.aminah@mayo.edu.

Förderung

  • NIMHD NIH HHS
  • National Institute on Minority Health and Health Disparities

Zitieren

APA

Brown, R., Smith, K. E., Shanshal, M. M., Dimou, A., Leventakos, K., Parikh, K., Mansfield, A. S., Molina, J. R., Goetz, M. P., Jatoi, A., & Cathcart-Rake, E. (2025). Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-10182-9

Vancouver

Brown R, Smith KE, Shanshal MM, Dimou A, Leventakos K, Parikh K, et al. Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-10182-9

BibTeX
@article{Brown2025,
  author = {Brown, Ryan and Smith, Katie E and Shanshal, Mohamed M and Dimou, Anastasios and Leventakos, Konstantinos and Parikh, Kaushal and Mansfield, Aaron S and Molina, Julian R and Goetz, Matthew P and Jatoi, Aminah and Cathcart-Rake, Elizabeth},
  title = {Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support},
  journal = {Supportive Care in Cancer},
  year = {2025},
  doi = {10.1007/s00520-025-10182-9}
}
Kostenlos starten →